Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Investors were hoping to see the results of Johnson & Johnson's Phase III trial for a potential one-dose vaccine for COVID-19 when the firm released its fourth quarter financial results on 26 January, but management implored patience. CEO Alex Gorsky told the earnings call that the company will release the Phase III data next week, the first week of February.
With J&J's deep financial pockets and broad manufacturing capacity, the company's COVID-19 vaccine could greatly impact the speed of a...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
